Sanctura (Trospium Chloride) - Indication
Sanctura is used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1
Primary Indication
Trospium chloride is an antimuscarinic (anticholinergic) medication specifically FDA-approved for managing overactive bladder syndrome. The drug targets three cardinal symptoms:
- Urge urinary incontinence - involuntary leakage accompanied by or immediately preceded by urgency
- Urgency - sudden compelling desire to urinate that is difficult to defer
- Urinary frequency - voiding too often during the day and night
Position in Treatment Algorithm
According to the AUA/SUFU guidelines, trospium is recommended as second-line therapy for OAB after behavioral interventions have been tried. 2 The treatment hierarchy is:
- First-line: Behavioral therapies (bladder training, pelvic floor muscle training, fluid management, weight loss)
- Second-line: Oral antimuscarinics including trospium, offered when behavioral therapy alone is insufficient
- Third-line: Neuromodulation or botulinum toxin for refractory cases
The American College of Physicians guidelines similarly position trospium as a pharmacologic option when bladder training has been unsuccessful in urgency incontinence. 3
Clinical Efficacy
Trospium demonstrates sustained effectiveness beginning at week 1 of treatment. In multicenter trials, it significantly:
- Decreased toilet voids per 24 hours
- Reduced urge incontinence episodes
- Increased volume per void
- Decreased urge severity and daytime frequency
- Improved quality of life scores 4
Long-term data shows efficacy is maintained through 48 weeks of treatment with once-daily extended-release formulation. 5
Unique Pharmacologic Properties
Trospium has three distinguishing characteristics among antimuscarinics:
- Quaternary ammonium structure - minimal central nervous system penetration, reducing cognitive side effects 6, 7
- Not metabolized by cytochrome P450 - lower potential for drug-drug interactions 6
- Primarily renally excreted unchanged - provides local bladder activity 7
These properties make it particularly suitable for elderly patients taking multiple medications, though dose reduction to 20 mg once daily is required in severe renal impairment (creatinine clearance <30 mL/min). 7
Important Contraindications
Do not prescribe trospium in patients with: 1
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma (requires ophthalmologist clearance if controlled)
- Known hypersensitivity to the drug
Use extreme caution in patients with: 2
- Impaired gastric emptying
- History of urinary retention (check post-void residual)
- Concurrent use of solid oral potassium chloride
Administration Details
Critical dosing instructions: 1
- Take on an empty stomach or at least 1 hour before meals (food reduces bioavailability by 74%)
- Standard dose: 20 mg twice daily with water
- Extended-release: 60 mg once daily
Common Side Effects
Most frequent adverse effects include dry mouth and constipation. Less common but notable effects are trouble emptying the bladder, blurred vision, and heat prostration (due to decreased sweating in hot environments). 1 Importantly, trospium shows minimal cognitive effects even with long-term use, including in Parkinson's disease patients. 8
Serious allergic reactions (angioedema) can occur - patients should discontinue immediately and seek emergency care if they develop facial/tongue/throat swelling or difficulty breathing. 1
Clinical Pearls
- No compelling evidence exists for differential efficacy among oral antimuscarinics; selection should be based on tolerability, adverse effect profile, ease of use, and cost 2
- Behavioral therapies can be combined with trospium for additive benefit 2
- The drug does not affect intraocular pressure but may decrease tear secretion, warranting ophthalmology referral if dry eye symptoms develop 9
- Individual dose titration (30-90 mg daily) based on efficacy and tolerability is safe and effective 10